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Abstract
 
Aims
 
Matrix metalloproteinases (MMPs) play a major role in wound healing: they can degrade all components of the
extracellular matrix. In diabetic foot ulcers there is an excess of MMPs and a decrease of the tissue inhibitors of MMPs
(TIMPs). This imbalance is probably one cause of impaired healing. However, little is known about changes in MMPs
during wound healing.
 
Methods
 
Sixteen patients with neuropathic diabetic foot ulcers participated. Wound fluid was collected regularly
during the 12-week follow-up period, for measurement of MMP-1, MMP-2, MMP-8, MMP-9 and TIMP-1. Results were
analysed by the degree of wound healing: good healers (defined by a reduction of at least 82% in initial wound surface at
4 weeks) and poor healers (reduction of less than 82% in wound surface at 4 weeks).
 
Results
 
In good healers, levels of MMP-8 and -9 secreted by inflammatory cells decreased earlier. The initial levels of
MMP-1 were similar in good and poor healers (
 
P
 
 
 
=
 
 0.1) but rose significantly at week 2 in good healers (
 
P
 
 
 
=
 
 0.039). There
was a significant correlation between a high ratio of MMP-1/TIMP-1 and good healing (
 
r
 
 
 
=
 
 0.65, 
 
P
 
 
 
=
 
 0.008). Receiver
Operator Curve (ROC) analysis showed that an MMP-1/TIMP-1 ratio of 0.39 best predicted wound healing
(sensitivity 
 
=
 
 71%, specificity 
 
=
 
 87.5%).
 
Conclusions
 
A high level of MMP-1 seems essential to wound healing, while an excess of MMP-8 and -9 is deleterious,
and could be a target for new topical treatments. The MMP-1/TIMP-1 ratio is a predictor of wound healing in diabetic
foot ulcers.
Diabet. Med. 25, 419–426 (2008)
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Introduction
 
Diabetic foot ulcers pose a major public health problem:
they are the leading cause of non-traumatic amputation in deve-
loped countries. The medical treatment of these chronic wounds
remains a challenge for clinicians. Better understanding of the
pathophysiology of these chronic wounds should improve
their treatment.
MMPs are a family of zinc endopeptidases capable of
degrading all the components of the extracellular matrix [1–3].
They are key players in every phase of the healing process: they
eliminate damaged protein, destroy the provisional extracellular
matrix, facilitate migration to the centre of the wound,
remodel the granulation tissue, probably control angiogenesis
[4] and also regulate the activity of some growth factors.
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MMPs are divided into sub-groups depending on the specificity
of their substrates. Collagenases (MMP-1 and -8) and gelatinases
(MMP-2 and -9) play a major role in the healing process. Their
activity is specifically inhibited by TIMPs, four of which have
been identified. With few exceptions, all the TIMPs are capable
of inhibiting all the MMPs, although TIMP-1 has a higher
affinity for MMP-1 and -9 and TIMP-2 for MMP-2 and -8.
Although essential in every phase of the healing process,
MMPs are finely regulated and a successful healing process is
dependent on a rigorous spatial and temporal pattern of
expression [5–7]. Whereas MMP levels decrease through the
normal wound-healing process, chronic wounds contain a
significantly higher level of proteases and pro-inflammatory
cytokines (tumour necrosis factor-
 
α
 
 and interleukin-1), as
well as lower levels of growth factors [8–11]. In particular,
collagenase [12,13] and gelatinase [14] activity is increased in
chronic wounds, while the TIMP-1 level is reduced compared
to acute wounds [12,14,15].
These data have led to a unifying pathophysiological
hypothesis: the inflammatory phase of healing is exaggerated
in chronic wounds (venous ulcers, pressure ulcers, diabetic
foot ulcers) [3,16] leading to an excess of proteases and inflam-
matory cytokines released by neutrophils and macrophages
[17,18]. Thus, the excess of proteases and MMPs in chronic
wounds is probably one of the reasons for poor healing by
breaking down too many components of the extracellular
matrix and by inhibiting growth factors that are essential for
tissue synthesis [3,11].
Few studies have measured MMP activity in wound fluid
from diabetic foot ulcers. Lobman 
 
et al.
 
 found that levels of
MMP-1, MMP-8, MMP-9 and activated MMP-2 were signific-
antly higher in diabetic foot ulcers and the level of TIMP-2
significantly lower than in acute wounds from non-diabetic
patients [19]. Likewise, there are very little data concerning the
change in MMP levels during the healing of chronic diabetic
foot ulcers.
The primary objective of this study was to describe changes
in MMP and TIMP levels during healing in diabetic foot ulcers,
and thus to improve our scant knowledge of this process. The
secondary objective was to search for any correlation between
changes in MMP and TIMP levels and wound healing, in
order to find possible predictors of healing.
 
Subjects and methods
 
Patients
 
This prospective pilot study recruited 16 consecutive Type 2
diabetic patients aged over 40 years from the Diabetology
Department of the Grenoble University Hospital from May
2005 to June 2006. Patients were eligible if they had: (1) a diabetic
foot ulcer rated 1 to 3, stage A according to the University
of Texas Wound Classification (not infected and no severe
arteriopathy); (2) a chronic wound (at least 30 days’ duration);
(3) a wound area larger than 0.5 cm
 
2
 
 at inclusion. Patients
were ineligible if they had an infected wound (based on the
International Consensus on The Diabetic Foot criteria 2003) or
arteriopathy of the lower limbs, characterized either by absence
of posterior tibial and pedal pulses or by an ankle/brachial
index 
 
<
 
 0.9. We excluded soft tissue infections, because bacteria
may secrete MMPs. We did not exclude osteomyelitis because
chronic osteomyelitis in particular may not necessarily be
associated with soft-tissue infection.
 
Study design
 
The study was approved by the institutional review board (Person
Protection Committee CPP of Grenoble University Hospital)
and each patient gave written informed consent. At each visit
[week 0 (W0), W1, W2, W4, W8 and W12], the wound area
was measured using a numeric photograph and appropriate
software (Mouseyes®, Salford, UK; http://www.hop.man.ac.uk/
staff/rtaylor).  Two samples of wound fluid were collected
using sterile absorbent paper strips placed on the edges of the
wound for 5 min, in order to measure MMP-1, -2, -8, -9 and
TIMP-1 levels. This method for the measurement of MMPs
has been validated for other sample types, particularly for
tears [20].
The local treatment was the same for all wounds. We followed
the protocol used for patients presenting with diabetic foot
ulcers in our department (local care given by a nurse every
2 days) and choice of the dressing according to our local
protocol (briefly, a wet dressing for dry wounds and an ab-
sorbent wound dressing for exudative wounds). No dressing
known to interfere with MMP levels (such as Beclapermine or
Promogran) was used.
 
Biological parameters
 
The assays of MMP-1, -2, -8 and -9 and TIMP-1 were per-
formed at the Enzymology Laboratory (Grenoble University
Hospital).
Protein elution from the Shirmer strips was performed by
stirring the strips in 1 ml of buffer (50 mM Tris, 50 mM NaCl,
0.05% Brij 35, pH 7.6) for at least 2 h at 
 
+
 
4
 
°
 
C.
The levels of MMP-2 and -9 were measured using zymography
[20]. Briefly, proteins were separated on an SDS-PAGE gel
copolymerized with 0.5 mg/ml gelatine. After incubation in a
buffer to activate the enzyme, the gel is stained with Coomassie
Blue (Sigma, Saint Quentin Fallavier, France): proteins with
gelatinolytic activity are thus detected as unstained bands. The
quantity of enzyme is assessed by densitometry of the lysis
bands, the area under the curve thus obtained being referred to
a standard scale of purified gelatinase. This method quantifies
both latent and activated forms of MMP-2 and -9, and, by addi-
tion, the total concentration of each gelatinase.
The concentrations of MMP-1, MMP-8 and TIMP-1 were
measured using an ELISA technique (R&D Systems, Lille, France
for MMP-1, Amersham, Orsay, France for MMP-8 and Oncogene
Research, VWR International, Fontenay sous Bois, France for
TIMP-1). To avoid possible variations caused by the amount
of fluid collected, protein concentration was assayed using the
Pierce method [21] and the concentrations of MMPs and
TIMP-1 were expressed as pg/
 
μ
 
g protein.
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Statistical analysis
 
The statistical software program SSPS® 11.0 (SPSS Inc., Chicago,
IL, USA) was used for statistical analyses, performed by the
Clinical Investigation Centre (CIC INSERM, Grenoble Univer-
sity Hospital). A threshold of 
 
α
 
 
 
=
 
 0.05% was used for all statistical
tests.
The 16 patients were divided into two sub-groups according
to the rate of ulcer healing. In a recent large prospective trial
[22], the mean percentage reduction in wound area over a 4-
week period was 82% [95% confidence interval (CI) 70–94] in
the group of patients whose wound had completely healed at
the end of the 12-week follow-up period. Therefore in our
study, a decrease in wound area of at least 82% at 4 weeks
defined the ‘good healers’ and a decrease in wound area of less
than 82% at 4 weeks defined the ‘poor healers’.
Quantitative parameters were expressed as the median and
25th and 75th percentiles. Qualitative parameters were expressed
in effectives and percentages. Non-parametric tests were used:
the Mann–Whitney or the Wilcoxon test and the Chi-squared
or Fisher test. The Spearman test was performed to detect
correlations between percentage decrease in wound area and
changes in the MMPs or TIMPs levels. However, the retro-
spective division into good and poor healers was not used for
detecting these correlations. ROC analysis was used to determine
whether the parameters had any predictive value with respect to
wound healing. Correlations between MMPs and healing, as
well as the ROC curves, were established using a population of
15 patients. One patient was excluded because he underwent
amputation at W8.
 
Results
 
Clinical data
 
Sixteen Type 2 diabetic patients [mean age 64 years (range 47–
84 years), 15 men and 1 woman] participated. The main
characteristics of the two sub-groups (seven good healers and
nine poor healers) are summarized in Table 1. The frequency of
diabetes complications (neuropathy, retinopathy, nephropathy,
arteriopathy of the lower limbs) was similar in the two groups.
However, four patients who satisfied the inclusion criteria
(at least one distal pulse) were later shown, by arterial Doppler,
to have developed an IPS 
 
<
 
 0.9 (respectively 0.4/0.5/0.8 and
0.84), suggesting arterial disease. Figure 1 shows the change in
wound size in both groups during the 12 weeks of follow-up. All
patients completed all the follow-up visits unless their wound
healed completely before the end of the study. In the good healers
group, all the wounds had completely closed before W12.
Oral antibiotics were given to the two patients (one in each
group) with proven osteomyelitis.
No patients received tetracyclines or chemically modified
tetracyclines, the only antibiotics known to influence MMP levels.
 
Kinetics of MMP expression during the wound-healing 
process
 
Initial levels of the different MMPs are shown in Table 2. There
were no significant differences in any parameter between the
Good healers (n = 7) Poor healers (n = 9)
Age (years) 60 (58–70) 61 (58–77)
Sex (M/F) 6/1 9/0
Duration of diabetes (years) 10 (10–25) 15 (10–25)
HbA1c (%) 12.4 (6.3–12.5) 9.1 (7.6–9.6)
Wound duration (months) 1 (1–1) 5* (2–6)
Initial wound area (cm2) 1.22 (0.95–1.29) 3.62* (2.23–5.1)
Initial wound depth (mm) 2 (1–2) 3.5 (2–5)
Frequency of osteomyelitis 2/7 (29%) 2/9 (22%)
ABi 1.10 (1.1–1.2) 1.10 (0.7–1.2)
HbA1c, glycated haemoglobin; ABi, ankle brachial index.
*P (good vs. poor healers) < 0.05.
Values are expressed as median (25–75th percentile).
Table 1 Patients’characteristics at inclusion
FIGURE 1 Wound area during the 12-week follow-up, expressed as a 
percentage of the initial area. The values correspond to medians for each 
group, with 25th and 75th percentiles. The number of patients whose 
wound is not completely healed is given in parentheses for each visit and 
each group. By week 8 7/7 patients had healed in the good healer group, 
whereas by week 12 3/9 patients had not healed in the poor healer group.
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two groups. During the 12 weeks of follow-up, the changing
profile of MMPs differed between groups (Figs  2 and 3).
Figure  2 shows that MMP-8 and -9 levels in good healers
remained stable between W0 and W2, before starting to
decrease from W2 onwards. The change in MMP-9 levels
between W0 and W4 did not reach significance (
 
P
 
 
 
=
 
 0.14). In
contrast, in poor healers MMP-8 and -9 levels remained con-
stant throughout the follow-up period. Moreover (Table 2 and
Fig. 3), the level of MMP-1 was significantly higher at W0 in
good healers compared to poor healers at week 2 [4.78 pg/
 
μ
 
g
of protein (CI 1.9–7.65) vs. 2.27 pg/
 
μ
 
g (CI 1.24–0.29); 
 
P
 
 
 
=
 
0.039]. MMP-1 level in good healers appeared to diminish
during the study whereas it remained stable in poor healers.
Over the same follow-up period, there was no significant
difference in the TIMP-1 level between the two groups.
MMP-2 level did not differ between the groups during the
study (Table 2 and data not shown), and no particular pattern
of change could be characterized.
 
Predictors of healing
 
The ratio between MMP and TIMP levels in wound fluid better
reflects the proteolytic environment of the wound than the two
measurements taken separately. The MMP-1/TIMP-1 ratio
was not significantly different at W0 in good healers compared
to poor healers (
 
P
 
 
 
=
 
 0.064). However, the percentage reduction
in wound area at W4 correlated positively with the MMP-1/
TIMP-1 ratio at W0 (
 
r
 
 
 
=
 
 0.65; 
 
P
 
 
 
=
 
 0.008) and at W2 (
 
r
 
 
 
=
 
 0.69,
 
P
 
 
 
=
 
 0.009). Hence the MMP-1/TIMP-1 ratio at W0 is a prog-
nostic indicator of complete healing at the end of the 12-week
follow-up period.
The ROC curve showed that an MMP-1/TIMP-1 ratio at W0
of 0.39 best predicts a reduction in wound area of at least 82%
at W4—i.e. predicts complete wound healing at W12—with a
sensitivity of 71% and a specificity of 87.5% (Fig. 4). Logistic
regression analysis showed that this ratio at W0 is a predictive
factor
 
 a priori 
 
independent of the wound area and depth.
However, in view of the small number of patients, the results
from this multivariate model should be treated with caution.
Table 2 Levels of matrix metalloproteinases at inclusion (week 0 visit) in 
pg/μg protein
Good healers (n = 7) Poor healers (n = 9)
MMP-1 4.88* 2.66
(2.43–10.32) (9–2.69)
Total MMP-2 22.89 42.22
(12.4–37.78) (23.63–57.46)
Activated MMP-2 5.41 5.75
(0–9.82) (4.95–7.88)
MMP-8 140.44 279.63
(70.8–342.2) (109.5–350)
Total MMP-9 461.6 479.4
(282–524) (246.4–876.6)
Activated MMP-9 0 20.85†
(0–7.16) (0–81.2)
TIMP-1 3.25 4.26
(2.93–5.01) (3.47–4.96)
Values are expressed as median (25–75th percentile).
MMP, matrix metalloproteinase; TIMP, tissue inhibitor of 
matrix metalloproteinase.
*P = 0.1.
†P = 0.068.
FIGURE 2 Levels of MMP-8 and MMP-9 for good and poor healers during the 12-week follow-up period (results are expressed as medians with 25th 
and 75th percentiles).
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FIGURE 3 Levels of MMP-1 and TIMP-1 for good and poor healers during the 12-week follow-up period (results are expressed as medians with 25th 
and 75th percentiles).
FIGURE 4 The ratio of MMP-1/TIMP-1 is a predictive factor for healing. The ROC analysis gives an area under the curve of 0.821 [confidence interval 
(CI) 0.6–1.04]. A ratio of 0.39 at week 0 has a sensitivity of 71% and a specificity of 87.5% for detecting a wound area reduction of at least 82% at 
week 4 (and thus predicting wound healing at week 12).
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Discussion
 
Remodelling of the extracellular matrix occurs in various
physiological processes (post-partum uterine involution,
ovulation, embryogenesis, odontogenesis, bone remodelling,
cutaneous healing etc.); consequently, its synthesis and destruc-
tion is strictly regulated [23]. MMPs are the main protease
family involved in this regulation. A disorder in the synthesis
of MMPs and/or alteration in the enzymes/inhibitors balance
have been shown in several pathological processes characterized
by disorganization of the extracellular matrix, such as rheumatoid
arthritis, formation of atheroma plaques, tumour development,
metastatic dissemination and chronic wounds [24].
Chronic ulcers are probably caused by an exaggeration of
their inflammatory phase [3,16]. This is supported by many
studies where levels of MMPs were higher in the exudates of
chronic wounds than in those of acute wounds, as in diabetic
foot ulcers [3,19]. However, it has been more assumed than
really shown that the ultimate healing of diabetic foot ulcers is
accompanied by a decrease in MMP levels. Longitudinal
studies of the change in MMP levels over the whole period of
the healing process were needed. In other respects, although
MMPs are deleterious when in excess, they are nevertheless
indispensable for good healing. This has been demonstrated by
studies in which topical broad spectrum inhibitors of MMPs
[GM 6001 (Ilomostat)] caused prolonged healing times com-
pared to a placebo [25,26]. Such negative results suggest that
each MMP plays a specific role in the healing process and that
our knowledge of the pathophysiology of chronic wounds is
incomplete. In particular the exact functions of the various
MMPs need to be explored.
Our study focused on a carefully selected population. We
wished to avoid contamination with cytokines or MMPs
produced by bacteria. Therefore, soft-tissue infection was an
exclusion criterion. Although grade 3 ulcers (UT) were indeed
included in our study (two patients in each group), osteomy-
elitis is not necessarily associated with soft-tissue infection.
Therefore we consider that levels of inflammatory cytokines
were the same in wounds with osteomyelitis as in wounds
without osteomyelitis.
There is currently no consensus as to the best method to
measure MMP activity in wounds. The two usual techniques
consist of collecting the wound fluid after occlusion with a
dressing or to take a biopsy at the wound edges. However
major differences in MMP concentration were observed
between these two measurement techniques [16]. We chose to
study local expression of MMPs in wound fluid, firstly because
it is accepted that fluid composition reflects the microenviron-
ment of the wound (with a mixture of tissue and serum proteins),
and secondly because biopsy could be harmful to small-size
wounds in diabetes. Samples were collected using absorbent
strips (Schirmer strips), which absorb the fluid by capillary
action. These sterile strips have been previously used in ophthal-
mology to measure MMP-2 and -9 concentrations in the
tears of patients with corneal grafts [20]. They can be used in
outpatient studies because of the rapidity of the sampling.
Moreover, MMP concentrations so measured are comparable
to those of other studies undertaken on wound fluids and
expressed in the same units (pg/
 
μ
 
g of protein) [10,16].
In our study, we described changes in MMP levels during 12
weeks follow-up in patients with homogeneous diabetic foot
ulcers. We showed two main differences between a group with
good healing prognosis and a group with poor prognosis.
Firstly, there is a statistically significant relationship between
the MMP-1/TIMP-1 ratio at study entry and good healing.
Indeed, MMP-1 is the major collagenase implicated in wound
healing: it has been shown that its specific proteolysis of type I
collagen (an essential component of the dermis) is indispensable
for keratinocyte migration and thus re-epidermization [27,28].
We hypothesize that the higher level of MMP-1 in good healers
is favourable by permitting the proliferative phase to be
completed. Furthermore, it has been suggested that an adapted
regulation of MMP-1 is essential to the proper progression of
the healing process [2]. The rise in TIMP-1 between W0 and W2
suggests regulation of MMP-1 activity for a correct healing.
Secondly, there is a decrease in the MMP-8 and -9 levels
from the second week after study entry in good healers, but not
in poor healers. This drop of both MMPs produced by inflam-
matory cells suggests a process of decline in the inflammatory
phase whilst healing proceeds, allowing the continuation of
the healing process to the next phase of proliferation. In the
same way, the higher level of activated MMP-9 in the poor
healer group supports the idea that an elevated level of some
MMPs (those secreted by inflammatory cells) is harmful to
healing. Likewise, Ladwig 
 
et al.
 
 described a higher level of
activated MMP-9 in a group of poorly healing pressure ulcers
compared to a group of good healers [16]. In their 56 patients,
the MMP-9/TIMP-1 ratio was positively correlated with poor
healing, which underlies the deleterious effect of an MMP-9
excess in chronic wounds. Interestingly, Lobmann 
 
et al.
 
 found
that the MMP-9/TIMP-2 ratio was significantly reduced in a
group of diabetic patients exhibiting a more rapid healing rate
when treated with a protease modulating matrix. However,
TIMP-2 seems less relevant as it inhibits preferentially MMP-
2 [29]. We also measured the MMP-9/TIMP-1 ratio in our
study, as well as the MMP-8/TIMP-1 ratio, but found no
statistical difference. We consider it biologically relevant that
MMP-1 was the predictive factor for wound healing because
MMP-1 is implicated in the migration of keratinocytes, while
MMP-8 and MMP-9 are synthesized by inflammatory cells.
Although MMP-8 and -9 are expressed at a level 10–100
times higher than other MMPs [12], MMP-1 and TIMP-1 are
localized in the same area of the cutaneous tissue because they
are both synthesized by the same cell type (keratinocytes and
fibroblasts) [10,13]. This permits the preferential inhibition of
MMP-1, particularly compared to MMP-9.
Lastly, the role of MMP-2 is not clear. As mentioned previ-
ously [16], the slight variations in its levels (because of its
constitutive expression in cutaneous tissue) suggest that
MMP-2 plays only a minor role in chronic wounds. Because
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MMP-2 is secreted by fibroblasts, produced mainly during
the proliferative phase, we hypothesize that its role is less
relevant in chronic wounds, where the inflammatory phase
predominates.
The principle weakness of the current study is the relatively
small number of patients and therefore the low statistical
power of our results. Another issue concerns our two popula-
tions that differ in terms of the wound surface area and
duration—two potential predictive factors for wound healing.
To control for this, we used a multivariate analysis, which
confirms that the MMP-1/TIMP-1 ratio is a predictive factor
independent of known clinical markers.
Nevertheless, these results allow us to formulate several
hypotheses. Firstly, the MMP-1/TIMP-1 ratio measured on
admission of a diabetic patient with a foot ulcer is a predictor
of healing and may allow treatment to be adapted accordingly.
Secondly, all the MMPs present in excess in diabetic foot ulcers
are not necessarily harmful to healing. Thus the development
of new topical treatments that act on MMPs should target
specific inhibitors of certain MMPs—probably those secreted
by inflammatory cells (MMP-8 and -9).
In conclusion, we have performed the first longitudinal
study describing the kinetics of expression of MMPs during
the healing process of chronic diabetic foot ulcers. This study
provides evidence for a role of the MMP-1/TIMP-1 ratio in the
prediction of healing.
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